Dr Alumkal on Standard Treatment Options For Patients With HRD-Altered mCRPC
Joshi Alumkal, MD, discusses treatment options for patients with metastatic castrate-resistant prostate cancer harboring homologous recombination deficient alterations, including PARP inhibitors.